Cosmos Health signs LOI to buy GMP drugmaker Doc Pharma

Cosmos Health

Cosmos Health

COSM

0.00
  • Cosmos Health entered a non-binding LOI to buy 100% of Doc Pharma, a European GMP pharmaceutical manufacturer.
  • Doc Pharma’s three-year average annual revenue was USD 6.7 million, with average annual gross profit of USD 3.2 million.
  • The target has an asset base of about USD 24 million, including a GMP-licensed 59,000-square-foot production facility.
  • The deal is expected to be immediately accretive, supporting margin expansion, profitability, and cash flow.
  • Transaction aims to deepen vertical integration, expand in-house manufacturing capacity, and broaden the product portfolio in generics and OTC drugs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606111531PRIMZONEFULLFEED9745778) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.